• AAPL 169.11
  • TSLA 162.2
  • AMZN 177.05
  • MSFT 408.96
  • INTC 34.605
  • EURUSD 1.0701
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. TO /
  3. ATE.TO

Antibe Therapeutics Inc. (ATE TO) stock market data APIs

C$0.135 -0.16(-54.2%) as of April 22, 2024

Antibe Therapeutics Inc. Financial Data Overview

-0.075
0.135
-
0.255
-0.155
0.15-1.23
15 638 K
53 009 K
9 713 K
-0.08
0.122
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ATE',
Type: 'Common Stock',
Name: 'Antibe Therapeutics Inc.',
Exchange: 'TO',
CurrencyCode: 'CAD',
CurrencyName: 'Canadian Dollar',
CurrencySymbol: 'C$',
CountryName: 'Canada',
CountryISO: 'CA',
ISIN: 'CA0370255097',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Antibe Therapeutics Inc. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 9 713 K
  • EBITDA -20 447 000
  • Earnings Per Share -0.35
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Antibe Therapeutics Inc. Earnings via APIs

  • Latest Release 2024-02-14
  • EPS/Forecast -0.11

Get Antibe Therapeutics Inc. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Antibe Therapeutics Inc. latest news via APIs

Antibe Therapeutics Inc.'s (TSE:ATE) Path To Profitability

We feel now is a pretty good time to analyse Antibe Therapeutics Inc.'s (TSE:ATE) business as it appears the company may be on the cusp of a considerable accomplishment. Antibe Therapeutics Inc., a bi...

Antibe Reports 2023 Year-End Results and Business Highlights

- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $3...
Do you have any questions?
support@eodhistoricaldata.com